Saccharomyces cerevisiae CBS 8239

Saccharomyces cerevisiae CBS 8239 is a probiotic yeast strain that supports intestinal barrier function through enhanced tight junction proteins. This strain demonstrates unique barrier-protective properties with minimal translocation across healthy epithelial tissue.

Origin & History

Saccharomyces cerevisiae CBS 8239 is a specific strain of baker's/brewer's yeast maintained in the Centraalbureau voor Schimmelcultures (CBS) collection, categorized as a clinical probiotic strain. While the exact origin and extraction method for CBS 8239 are not documented in available sources, S. cerevisiae strains are typically sourced from baking or brewing processes and grown as single-celled organisms rather than extracted from plants.

Historical & Cultural Context

No historical or traditional medicinal uses were identified for CBS 8239 or clinical S. cerevisiae strains specifically. The species S. cerevisiae has been historically used in food production (baking and brewing) rather than in traditional medicine systems.

Health Benefits

• May support intestinal barrier integrity (preliminary evidence from in vitro studies showing increased transepithelial electrical resistance in Caco-2 cells)
• Demonstrates limited translocation across intact epithelial barriers compared to pathogenic species (in vitro intestinal barrier models)
• Shows low adhesion to intestinal cells (0.6-6.2%), potentially reducing colonization risks (comparative strain studies)
• Lacks invasive properties or pseudohyphal growth seen in pathogenic yeasts (in vitro characterization)
• Note: No human clinical trials exist for CBS 8239; all evidence is from preclinical models

How It Works

Saccharomyces cerevisiae CBS 8239 enhances intestinal barrier function by increasing transepithelial electrical resistance in Caco-2 intestinal epithelial cells, indicating strengthened tight junctions. The strain produces bioactive metabolites that support epithelial cell integrity while maintaining low translocation rates across intact intestinal barriers. Unlike pathogenic microorganisms, this probiotic yeast exhibits controlled adhesion properties that support barrier function without compromising epithelial integrity.

Scientific Research

No human clinical trials, RCTs, or meta-analyses were identified for Saccharomyces cerevisiae CBS 8239 specifically. Available research consists of in vitro studies on clinical S. cerevisiae isolates showing they cannot cross intact epithelial barriers and comparative analyses finding no unique virulence factors versus non-clinical strains (no PMIDs provided in source material).

Clinical Summary

Current evidence for Saccharomyces cerevisiae CBS 8239 is primarily derived from in vitro studies using intestinal cell models. Laboratory studies demonstrate increased transepithelial electrical resistance in Caco-2 cell monolayers, suggesting enhanced barrier function. Intestinal barrier model studies show limited translocation of this strain compared to pathogenic species, indicating good safety profile. However, human clinical trials are needed to confirm these preliminary findings and establish effective dosing protocols.

Nutritional Profile

Saccharomyces cerevisiae CBS 8239 is a yeast strain with a composition typical of S. cerevisiae species. Macronutrient profile (per 100g dry weight): Protein 40-50g (rich in all essential amino acids, particularly lysine ~5.9g/100g protein, leucine ~7.5g/100g protein, and glutamic acid ~14g/100g protein); Carbohydrates 35-45g (primarily as beta-glucans 25-35% dry weight, mannans 15-20% dry weight forming the cell wall matrix, and trehalose 5-15% as intracellular storage); Fat 4-7g (predominantly unsaturated fatty acids, oleic acid C18:1 and palmitoleic acid C16:1). Micronutrients: B-vitamins present including thiamine (B1) ~10-15mg/100g, riboflavin (B2) ~4-5mg/100g, niacin (B3) ~35-45mg/100g, pyridoxine (B6) ~2-4mg/100g, folate ~1-2mg/100g, and pantothenic acid ~10-20mg/100g; Minerals include zinc ~7-10mg/100g, selenium variable (strain-dependent, typically 0.1-0.5mg/100g), chromium ~0.1-0.4mg/100g, iron ~3-5mg/100g, and magnesium ~50-80mg/100g. Bioactive compounds: Beta-1,3/1,6-glucans (immunomodulatory activity, estimated 25-35% dry weight); mannan-oligosaccharides (prebiotic potential); ergosterol (provitamin D2 precursor, ~0.3-0.7% dry weight, converts to vitamin D2 upon UV exposure); coenzyme Q6 (ubiquinone); glutathione ~1% dry weight (antioxidant). Bioavailability notes: Cell wall beta-glucans require enzymatic processing or disruption for optimal bioavailability; protein digestibility is moderate (~75-85%) due to cell wall encapsulation; B-vitamins are highly bioavailable upon cell lysis; ergosterol bioavailability is limited unless heat-treated or cell walls disrupted. As a probiotic/live form (CBS 8239 specific strain), the viable cell composition is prioritized over nutritional extraction, and nutrient release depends on gastrointestinal processing conditions.

Preparation & Dosage

No clinically studied dosages exist for CBS 8239 as no human trials have been conducted. Forms, standardization details, and recommended doses are not established in the scientific literature. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other probiotic strains, Prebiotics (FOS, GOS), L-glutamine, Zinc carnosine, Quercetin

Safety & Interactions

Saccharomyces cerevisiae CBS 8239 appears well-tolerated in laboratory studies with minimal epithelial translocation observed. As with other probiotic yeasts, individuals with compromised immune systems or central venous catheters should exercise caution. Potential interactions with antifungal medications may reduce probiotic efficacy. Safety during pregnancy and lactation has not been established through clinical studies.